Coley Fluid stimulates an immune response that can be sufficiently powerful to induce the regression of cancer. 

Dr. William Coley developed Coley Fluid in 1893. The first immune therapy for cancer became a mainstream treatment manufactured and distributed worldwide by several pharmaceutical companies. Coley Fluid was responsible for numerous well-documented complete remissions of advanced cancers that do not respond to modern therapies.  

After Dr. Coley’s death in 1936, the use of Coley Fluid and the number of commercial suppliers declined. In the United Kingdom, the Lister Institute of Preventative Medicine ceased production in 1943, and in the United States, Parke Davis & Company ceased production in 1951. The German pharmaceutical company Südmedica ceased production in 1981 leaving no remaining commercial suppliers, and Coley Fluid was on the brink of becoming a footnote to medical history. 

The decline of Coley Fluid coincided with the continued development and increased use of radiotherapy and chemotherapy. An obvious reason was the newer treatments were less labour intensive, but the fundamental reason for the decline of Coley Fluid was the lack of understanding of its mechanism of action. Without medical knowledge to guide clinical use, Coley Fluid results were unpredictable and inconsistent. 

In 2002, the respected journal Science published Polly Matzinger’s groundbreaking paper “The Danger Model” that laid the essential groundwork to understanding the mechanism of action of Coley Fluid. 

In 2003, two publications made the case for reviving Coley Fluid: “Dr William Coley and Tumour Regression” by Stephen Hoption Cann, Hans van Netten and Chris van Netten, and Spontaneous Regression Cancer and the Immune System by Donald H. MacAdam. In 2004, MacAdam and Hoption Cann decided to work together in the development of an optimal version of Coley Fluid with administration protocols based on a modern understanding of immunology. With support from a group of private investors, MBVax Bioscience was founded in 2005. 

MBVax Bioscience has developed an optimized version of Coley Fluid and an administration protocol based on a modern understanding of cancer immunology.  

MBVax Coley Fluid is an experimental drug that has not been approved by health regulators in any country. In Canada and some other countries, the use of Coley Fluid is prohibited, even on a compassionate use basis. However, Coley Fluid may be available in countries that allow late-stage cancer patients no longer responsive to existing therapies access to experimental drugs, in countries with “Therapy Freedom” laws where physicians have the right to prescribe experimental drugs, in countries that authorize certain clinics to treat cancer patients with experimental drugs, and health regulators in some countries have granted physicians permission to import and administer MBVax Coley Fluid. 

MBVax Bioscience administers a compassionate use program under which Coley Fluid is supplied to physicians who have read and understand the clinical protocol and are legally able to import and administer Coley Fluid under the laws and regulations of their country.

The patients who have used MBVax Coley Fluid are almost exclusively end-stage, suffering from the many effects of previous treatments and with few remaining treatment options. Of cancer patients receiving at least four weeks Coley Fluid therapy, physicians report these results (including patients continuing to receive therapy):

• 94% of patients have benefited from therapy including improvement in pain, appetite, depression, mobility, and/or regression of cancer. 
• 70% of patients have achieved confirmed regression of cancer.
• Twelve patients have achieved complete remission (no detectable cancer).

Physicians have reported confirmed regressions in 17 different types of advanced cancer: breast, brain, cervical, colon, esophageal, liver, lung, lymphoma, melanoma, multiple myeloma, ovarian, pancreas, prostate, rectal, sarcoma, stomach and tongue. Complete remissions (no remaining cancer) have been reported in two advanced lymphomas, eight advanced breast cancers, and one each in advanced lung cancer and stomach cancer.

Click on MBVax Results for more complete information.